Actinium Pharmaceuticals, Inc. (Delaware)

As of June 30, 2026, Actinium Pharmaceuticals, Inc. carries a market capitalization of 26.98M, placing it among publicly traded companies globally. Its enterprise value stands at -3.77M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Actinium Pharmaceuticals, Inc.'s next confirmed earnings release is scheduled for November 23, 2026.

As of June 30, 2026, Actinium Pharmaceuticals, Inc. has 31.37M shares outstanding.

As of June 30, 2026, Actinium Pharmaceuticals, Inc. trades at a trailing price-to-earnings ratio of 2.72. The price-to-sales ratio is 0.88, and the price-to-book ratio stands at 1.02.

As of June 30, 2026, Actinium Pharmaceuticals, Inc. maintains a current ratio of 4.08, meaning it holds 4.1x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Actinium Pharmaceuticals, Inc. posted a return on equity (ROE) of 45.86, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 36.79 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 21.92, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 43.54, useful for judging operating efficiency across full business cycles. The company generates approximately 1.10M in revenue per employee across its workforce of 28.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Actinium Pharmaceuticals, Inc.'s stock has gained approximately 14.22% over the past 52 weeks. The 50-day moving average sits at 1.01, while the 200-day moving average is 0.97.

Over the twelve months ended June 30, 2026, Actinium Pharmaceuticals, Inc. generated 30.71M in revenue and converted that into 9.90M in net income, yielding earnings per share of 0.32. EBITDA reached 9.13M, while operating income came in at 8.36M.

As of June 30, 2026, Actinium Pharmaceuticals, Inc. holds 31.92M in cash and equivalents against 1.17M in total debt, resulting in a net debt position of -31.92M. Total book value stands at 26.52M, with working capital of 24.93M providing operational flexibility.

Actinium Pharmaceuticals, Inc. produced -19.84M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -511,175.20 in capital expenditures, free cash flow totaled -20.35M - equivalent to -0.65 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of 27.23 and net profit margin of 32.23 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -75.69: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.70, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Actinium Pharmaceuticals, Inc. shareholders.

Actinium Pharmaceuticals, Inc.'s most recent stock split took place on August 11, 2020 with a 30:1 split ratio.

As of June 30, 2026, Actinium Pharmaceuticals, Inc. has an Altman Z-Score of -9.12, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.